Profusa (NASDAQ:PFSA) Trading 6.6% Higher – Here’s What Happened

Profusa, Inc. (NASDAQ:PFSA) shares shot up 6.6% during mid-day trading on Monday . The stock traded as high as $2.67 and last traded at $2.59. 103,158 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 3,299,098 shares. The stock had previously closed at $2.43.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PFSA shares. Weiss Ratings raised Profusa from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. Wall Street Zen raised shares of Profusa to a “sell” rating in a research note on Saturday, August 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Profusa Price Performance

The firm has a fifty day simple moving average of $5.50 and a 200 day simple moving average of $36.64. The company has a market cap of $1.18 million, a price-to-earnings ratio of -0.00 and a beta of 0.49.

Profusa (NASDAQ:PFSA) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($151.80) EPS for the quarter.

Insider Buying and Selling at Profusa

In other news, major shareholder Financial Lp Hrt sold 10,602 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $3.56, for a total value of $37,743.12. Following the completion of the sale, the insider directly owned 18,549 shares in the company, valued at approximately $66,034.44. This trade represents a 36.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders acquired 4,308 shares of company stock valued at $16,594 in the last three months. Company insiders own 15.00% of the company’s stock.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.